M

Mass General Brigham

Early-stage life science venture investor

Emergency Department Treatment Area Coordinator Human Resources Nights - Every other weekend 11p-7:30a

Part-Time
$19.81 - $28.30/hr
Entry
Bachelor's, Associate's
Boston, MA, USA
In Person
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • A high school diploma or GED is required.
  • Ability to handle sensitive and confidential information appropriately.
  • Sound judgment and critical thinking.
  • Ability to prioritize effectively and handle multiple tasks in a busy environment.
  • Strong organizational and follow-through skills.
  • Accuracy and attention to detail.
  • Strong customer service, interpersonal, and communication skills.
  • Ability to be flexible and function within a team environment.
  • Ability to maintain composure in stressful circumstances.
  • Basic computer skills or the ability to learn Microsoft Outlook, Epic, and related computer systems.
  • Must work up to six holidays per year.
Responsibilities
  • Coordinate administrative and reception support functions in the Emergency Department under the general direction of the ED Administrative Supervisor or Manager.
  • Facilitate communication within and across treatment areas and external hospital departments.
  • Arrive patients, coordinate their arrival to treatment areas, monitor patient disposition to aid throughput, and facilitate movement to test sites and procedure areas.
  • Organize patient belongings, paperwork, and discharge transportation; triage telephone calls and respond accordingly.
  • Monitor entrances to secured areas and screen people before allowing entry.
  • Receive patients’ relatives and visitors and direct them to appropriate individuals; provide support to ED staff.
  • Train and maintain competency to cover seven treatment areas with different workflows and requirements, as well as the ED Main Desk.
  • Perform patient arrival procedures, enter demographic data and medical record numbers, follow up on unidentified patients, place and verify identification bands, and complete bedside registration interviews.
  • Coordinate visitor redirection, social services contact for trauma patients whose families have not been notified, emergency-release blood product pickup, referral and CMED note linkage, patient rooming in Epic, evidence-related belongings procedures, patient monitoring-system data entry, valuables handling, and patient paperwork routing.
  • Review treatment-area census in Epic and update it for accuracy; coordinate patient transport for tests, inpatient units, observation units, and other needs, and communicate with transport staff.
  • Monitor Epic Trackboard handoffs and transfer timing, use the “Back In Bed” and “Back To Bed” functions, ensure paperwork accompanies patients, and support alternative-pathway admissions to NWH.
  • Facilitate communication between patients or visitors and providers or nurses, and provide nonclinical direction and advice.
  • Respond to clinician requests, refer unresolved requests to Charge, obtain Blood Bank requisitions, and arrange blood-product tubing or pickup.
  • Observe waiting and treatment areas, report disruptions or changes in patient status, monitor the pediatric waiting area, and support area security and visitor limits at clinicians’ direction.
  • Understand Section 12 paperwork and identify patients under Section 12; notify Security or clinicians if such patients attempt to leave.
  • Troubleshoot hardware and software issues, open Help Desk tickets when needed, and notify Charge.
  • When directed by Nursing, explain Violence Against Women Act billing options, complete required paperwork, and notify Registration and Billing of updates.
  • Follow SANE paperwork policy and arrange SANE nurse parking through Charge.
  • Collect, label, and route provider paperwork; check patient locations in Epic; run reports on patient locations and other information; review referrals and notify Charge about unlinked referrals.
  • Set up requested patient communication aids or page Interpreter Services; use Epic’s Belongings function to document valuables and belongings.
  • Check the safe log, notify the Charge Coordinator, and ensure valuables and belongings are returned before departure.
  • Arrange discharge transportation at clinicians’ direction and ensure the physician completes the Ambulance Necessity Form.
  • For interfacility transfers, assemble paperwork, ensure the COBRA form is completed and signed, send the original with the patient, and file copies.
  • For patient deaths, label the Report of Death, assemble Medical Examiner paperwork, provide it to Charge with relevant medical records, and assist with returning valuables to families.
  • Dismiss patients from Epic and the monitoring system, and process, label, alphabetize, and file dismissal paperwork.
  • Answer treatment-area calls, direct calls or assist callers, follow protocols for off-scope patients, record and communicate laboratory results, and redirect stat-result calls from the Microbiology lab.
  • Use the intercom and Voalte systems for communication, initiate requested pages, help patients contact families, call ancillary departments, troubleshoot Voalte phones, reconcile phone inventory, and cover the main ED phone lines.
  • Receive visitor-permission requests from Front Desk Reception, confirm permission with the patient’s nurse, greet and direct visitors, follow up on visitor inquiries, and redirect or ask visitors to leave when requested by treatment-area staff.
  • For patients called to the operating room, print and deliver an additional identification band, secure or arrange transfer of valuables and belongings, and assemble and deliver labeled paperwork.
  • Order and stock specified forms and clerical supplies, obtain supplies and equipment requested by clinical staff, and arrange equipment replacement or repair.
  • Page Environmental Services to clean discharge bays and contact Buildings and Grounds, Network Services, Biomedical Engineering, or other departments for maintenance repairs.
  • Communicate unresolved supply, equipment, physical-plant, and safety issues to the Charge Coordinator or Team Lead.
Desired Qualifications
  • An associate or bachelor’s degree is preferred.
  • Experience in a health care setting is preferred.
  • One year of related work experience is preferred.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.